Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supreme Court Denial Of Apotex Cert Against Pfizer Could Negatively Impact Generic Firms

This article was originally published in The Pink Sheet Daily

Executive Summary

Canadian company had sought judgment on validity of a Zoloft patent before launching a sertraline generic.

You may also be interested in...



KV Petitions FDA To Retain 180-Day Exclusivity For Generic Toprol-XL Doses

FDA has already issued tentative approval to Sandoz for the two doses.

KV Petitions FDA To Retain 180-Day Exclusivity For Generic Toprol-XL Doses

FDA has already issued tentative approval to Sandoz for the two doses.

Declaratory Judgment Ruling From U.S. Supreme Court Could Impact Licensing Deals, ANDAs

High court is mulling MedImmune's right to challenge a patent licensed from Genentech while continuing to make royalty payments.

Related Content

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel